The U.S. Food and Drug Administration is reviewing more evidence of serious risks of anemia drugs used for cancer patients. The drugs in question are Aranesp and Procrit.Two new studies have found that patients with breast or advanced cervical cancer who were treated with the drugs died sooner than similar patients that were not given the drugs. The findings are consistent with six previous studies that prompted stronger warning labels on the anemia drugs in November of last year. The FDA says the new evidence will be discussed at a public meeting in the next few months. In the meantime, the agency recommends that healthcare providers review the risks and benefits of the drugs and discuss the information with the patients.